Aprea Therapeutics reports confirmed partial response in Phase 1 APR-1051 cancer trial
APRE•Aprea Therapeutics reported interim Phase 1 results for APR-1051, including a confirmed partial tumor response in a patient with PPP2R1A-mutated uterine cancer that remained ongoing beyond 10 months. The company plans to expand enrollment to at least 50 patients and expects dose escalation and backfill enrollment to finish in the second quarter of 2027.
1. Interim trial results
Aprea Therapeutics announced interim Phase 1 results for its WEE1 inhibitor APR-1051, including partial tumor responses in patients with PPP2R1A-mutated uterine cancers. One confirmed response remained ongoing beyond 10 months. The reported safety profile supported continued dose optimization, while serious lung inflammation and reduced neutrophil counts were also reported.
2. Planned expansion
The planned expansion targets at least 50 patients with uterine serous carcinoma or cyclin E-overexpressing, platinum-resistant ovarian cancer. Dose escalation and backfill expansion enrollment are expected to finish in the second quarter of 2027.




